{"id":"peginterferon-alfa-2a-ribavirin-amantadine","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"20-50","effect":"Hematologic abnormalities (anemia, thrombocytopenia, leukopenia)"},{"rate":"10-30","effect":"Psychiatric effects (depression, anxiety)"},{"rate":"5-15","effect":"Thyroid dysfunction"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Nausea"},{"rate":"20-40","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa-2a is a long-acting interferon that activates innate immunity and has direct antiviral properties. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis and may enhance interferon-mediated immune responses. Amantadine is an adamantane derivative that blocks viral uncoating and has immunomodulatory effects. Together, this combination targets multiple stages of viral replication and enhances antiviral immunity.","oneSentence":"This triple-drug combination uses peginterferon alfa-2a and ribavirin as antivirals with immunomodulatory effects, plus amantadine as an additional antiviral agent, to suppress viral replication and enhance immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:52.466Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT00221624","phase":"PHASE3","title":"Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2001-11","conditions":"HCV Infection, Hepatitis C, Chronic","enrollment":131},{"nctId":"NCT00299923","phase":"PHASE3","title":"Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy","status":"UNKNOWN","sponsor":"University of Hamburg-Eppendorf","startDate":"2005-11","conditions":"Hepatitis C, Chronic, Relapse","enrollment":300},{"nctId":"NCT00127777","phase":"PHASE4","title":"Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)","status":"UNKNOWN","sponsor":"University Hospital, Saarland","startDate":"2002-07","conditions":"Hepatitis C, Chronic","enrollment":700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Peginterferon alfa-2a, Ribavirin, Amantadine","genericName":"Peginterferon alfa-2a, Ribavirin, Amantadine","companyName":"University of Hamburg-Eppendorf","companyId":"university-of-hamburg-eppendorf","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination uses peginterferon alfa-2a and ribavirin as antivirals with immunomodulatory effects, plus amantadine as an additional antiviral agent, to suppress viral replication and enhance immune response. Used for Chronic hepatitis C virus infection (phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}